Blue Water Acquisition III - Unit. (BLUWU) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Blue Water Acquisition III - Unit. (BLUWU) has outperformed Molecular Partners (MOLN) over the past year, gaining 4.7% versus a loss of 1.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLUWU | MOLN |
|---|---|---|
| Share price | $10.50 | $3.85 |
| Market cap | — | $147.48M |
| 1-day change | 0.00% | +1.05% |
| YTD return | -0.47% | -11.68% |
| 1-year return | +4.69% | -1.03% |
| 5-year return | — | -80.76% |
| EPS (TTM) | — | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.85 | $5.36 |
| 52-week low | $10.03 | $3.53 |
| Distance from 52-week high | -18.29% | -28.17% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +169.35% |
| Average volume | 49 | 1.15K |
| Shares outstanding | — | 38.31M |
| Employees | — | 134 |
| Sector | Financial Services | Health Care |
| Industry | Shell Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Blue Water Acquisition III - Unit. in Financial Services and Molecular Partners in Health Care.
About Blue Water Acquisition III - Unit.
BLUWU stock →Blue Water Acquisition Corp. III does not have significant operations.
Financial Services · Shell Companies
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
BLUWU vs MOLN FAQ
Which stock has performed better over the past year, BLUWU or MOLN?
BLUWU returned +4.69% over the past 12 months, compared with -1.03% for MOLN (price return, excluding dividends). Past performance does not predict future results.
Are Blue Water Acquisition III - Unit. and Molecular Partners in the same industry?
No. Blue Water Acquisition III - Unit. is in the Financial Services sector, while Molecular Partners is in Health Care.